Global event on enhancing the sustainability of investment for vaccine manufacturing in Africa.
27-29 June 2023
United Nations Conference Centre, UNECA, Addis Ababa, Ethiopia

Presentation of opportunities for investment and partnerships on vaccines and biopharmaceuticals.

### A. Who we are, & what we do

The International Vaccine Institute (IVI) is an international organization dedicated to accelerating the development and introduction of vaccines to protect people, especially children, in developing countries against deadly infectious diseases. It was established in 1997 and is headquartered in Seoul, South Korea. IVI opened its European Regional Office in Sweden in Sep 2022, and its Country Office in Austria in Nov 2022, and both offices are working closely with IVI HQ to expand our international footprint. We operate as an independent organization under a treaty signed by its member states.

IVI's primary goal is to discover, develop, and deliver safe, effective, and affordable vaccines to prevent infectious diseases that disproportionately affect populations in developing countries. The institute collaborates with academic institutions, governments, industry partners, and international organizations to research, develop vaccines, and strengthen immunization programs. IVI has the skills, knowledge, and resources to execute end-to-end vaccine R&D and to build capacity across the entire vaccine value chain—from discovery to animal and clinical testing to vaccine manufacturing, regulatory approval, and delivery. IVI supports epidemiological and health economics research; leads vaccine discovery and pre-clinical testing; manages clinical trial partnerships; oversees vaccine licensure and WHO prequalification; facilitates technology transfer to manufacturers; and conducts post-introduction impact studies. IVI also maintains state-of-the-art vaccine research capabilities at our Seoul headquarters, including BSL 3 labs and animal research facilities, and is equipped to support work in molecular biology, microbial genetics, bioinformatics, and immunology.

**IVI's Current Vaccine Portfolio:**

IVI focuses on developing vaccines for diseases such as cholera, typhoid fever, invasive non-typhoidal salmonella (iNTS), and other emerging and endemic infectious diseases affecting developing countries. IVI also works on vaccines targeting emerging infectious diseases and neglected tropical diseases. IVI's portfolio includes:

- **Cholera Vaccine:** IVI has been involved in developing and introducing an oral cholera vaccine (OCV), which has demonstrated efficacy in preventing cholera outbreaks. IVI provides technical assistance and supports countries in integrating OCV into their national immunization programs. IVI still works on OCV to improve its formulation to reduce the production cost and increase the vaccine volume, given the global stockpile’s need.
• **Typhoid Vaccine**: IVI has been actively developing new typhoid vaccines (i.e., Typhoid conjugate vaccine) and conducting clinical trials to assess their safety and efficacy. These vaccines aim to provide long-term protection against typhoid fever. Korea FDA approved the TCV for export-only license and is on its way to WHO PQ.

• **Invasive Non-typhoidal Salmonella (iNTS) Vaccine**: IVI is researching and developing vaccines to prevent iNTS disease, primarily affecting young children and immunocompromised individuals in sub-Saharan Africa.

**Focus and Specialization:**
IVI specializes in vaccine research and development, focusing on diseases that predominantly affect populations in low- and middle-income countries. The institute emphasizes the development of vaccines that are affordable, accessible, and suitable for resource-limited settings. IVI also contributes to building vaccine manufacturing and delivery capacity in developing countries.

**Capacity:**
IVI has a multidisciplinary team of scientists, researchers, and public health experts who work collaboratively to advance vaccine development and implementation. The institute has state-of-the-art laboratories and facilities for conducting research and clinical trials. IVI also provides technical assistance to governments and organizations to strengthen their vaccine manufacturing capabilities and immunization programs.

### B. What are we offering

The International Vaccine Institute (IVI) offers various opportunities for partnership and collaboration with other partners, including governments, academic institutions, industry partners, and international organizations.

1. **Research Collaboration**: IVI collaborates on vaccine research and development projects with partners. This includes jointly conducting pre-clinical and clinical studies, sharing scientific expertise, and contributing to the design and implementation of research projects.

2. **Technology Transfer and Licensing**: IVI can license its vaccine technologies and provide technical assistance for their transfer to interested partners. This enables partners to manufacture and distribute IVI-developed vaccines, ensuring broader access to life-saving immunizations.

3. **Training and Capacity Building**: IVI offers training programs (e.g., IVI International Vaccinology Course and Biomanufacturing course with support from MOHW and WHO) and workshops to build the capacity of scientists, researchers, and healthcare professionals in various aspects of vaccine development production, and immunization program management. These training initiatives aim to enhance local expertise and strengthen the workforce in partner countries.
4. **Feasibility Studies:** IVI can conduct feasibility studies to assess the suitability and potential impact of introducing specific vaccines or immunization programs in a particular setting. These studies provide valuable insights and evidence to inform decision-making processes and optimize resource allocation.

5. **Technical Assistance:** IVI provides technical assistance to governments, national immunization programs, and organizations to strengthen vaccine manufacturing capabilities, regulatory systems, and immunization strategies. This support includes guidance on vaccine production, quality control, cold chain management, and vaccine supply chain optimization.

6. **Policy and Advocacy Support:** IVI collaborates with partners to advocate for vaccination’s importance and shape vaccine development, introduction, and access policies. IVI's expertise and evidence-based recommendations can contribute to developing effective immunization policies at the national and global levels.

IVI's partnership opportunities and resources aim to foster collaboration, knowledge exchange, and capacity development in vaccine research and development, leading to improved access to life-saving vaccines for populations in need.

### C. What are we looking for

The International Vaccine Institute (IVI) actively seeks partnerships with businesses, finance providers, and technology providers to enhance its capabilities and achieve its mission of improving global health through vaccine development and access.

1. **Project Support:** IVI welcomes financial support from businesses and finance providers to sustain and expand development programs in the African continent. This includes funding for basic and applied research, clinical trials, epidemiology research, vaccine manufacturing, and capacity-building initiatives. Financial contributions help IVI advance its pipeline of vaccines and accelerate their introduction in low- and middle-income countries.

2. **Industry Collaboration:** IVI actively collaborates with vaccine manufacturers and biotechnology companies to develop and produce vaccines that are affordable, accessible, and suitable for resource-limited settings. Partnerships with businesses in the pharmaceutical industry can contribute to scaling up vaccine production, ensuring the availability of essential vaccines, and improving global vaccine supply security.

3. **Advocacy and Public-Private Partnerships:** IVI seeks partnerships with businesses and industry leaders to advocate for increased vaccine research, development, and access investment. We trust that Public-private partnerships can strengthen IVI's capacity to influence policies, mobilize resources, and address barriers to vaccine access and delivery.

4. **Technical Expertise and Knowledge Exchange:** IVI values partnerships that exchange technical expertise, scientific knowledge, and best practices. Collaborations with
businesses, technology providers, and experts in relevant fields foster innovation, improve research methodologies, and strengthen IVI's capabilities in vaccine development, clinical trials, and immunization program management.

By engaging with businesses, finance providers, and technology providers, IVI aims to leverage its resources, expertise, and networks to advance its mission and accelerate the development and delivery of life-saving vaccines to those most in need.

IVI’s core mission is to support capacity building through the project’s execution. And regarding Africa’s effort to strengthen its vaccine R&D, IVI is happy to offer its support to catalyze a freestanding African organization that will bridge an end-to-end vaccine R&D ecosystem with sustainable manufacturing as its final objective.

**Contact:**
Junhee Lee, Business Development Manager, jaybrant.lee@ivi.int
Andrea Kim, Business Development Associate, Andrea.kim@ivi.int

**Website:** [https://www.ivi.int/](https://www.ivi.int/)